Clinical Trial Update: Proof of Biological Activity of SAR100842 in Systemic Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial of SAR100842 in systemic sclerosis demonstrated biological activity, providing proof of concept in a completed study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• SAR100842

Snippet

Sponsor: Sanofi | Conditions: Systemic Sclerosis | Phase 2 | Status: COMPLETED